Section 246-922-410. Approval of substance abuse monitoring programs.  


Latest version.
  • The board will approve the monitoring program(s) which will participate in the recovery of podiatric practitioners. The board will enter into a contract with the approved substance abuse monitoring program(s).
    (1) An approved monitoring program:
    (a) May provide evaluations and/or treatment to the participating podiatric practitioners;
    (b) Shall enter into a contract with the podiatric practitioner and the board to oversee the podiatric practitioner's compliance with the requirement of the program;
    (c) Shall maintain records on participants;
    (d) Shall be responsible for providing feedback to the podiatric practitioner as to whether treatment progress is acceptable;
    (e) Shall report to the board any podiatric practitioner who fails to comply with the requirements of the monitoring program;
    (f) Shall provide the board with a statistical report and financial statement on the program, including progress of participants, at least annually, or more frequently as requested by the board;
    (g) Shall provide for the board a complete biennial audited financial statement;
    (h) Shall enter into a written contract with the board and submit monthly billing statements supported by documentation;
    (2) Approved monitoring program staff must have the qualifications and knowledge of both substance abuse/dependency and the practice of podiatric medicine and surgery as defined in chapter 18.22 RCW to be able to evaluate:
    (a) Drug screening laboratories;
    (b) Laboratory results;
    (c) Providers of substance abuse treatment, both individual and facilities;
    (d) Podiatric practitioner support groups;
    (e) Podiatric practitioners' work environment; and
    (f) The ability of the podiatric practitioners to practice with reasonable skill and safety.
    (3) The program staff of the approved monitoring program may evaluate and recommend to the board, on an individual basis, whether a podiatric practitioner will be prohibited from engaging in the practice of podiatric medicine and surgery for a period of time and restrictions, if any, on the podiatric practitioner's access to controlled substances in the workplace.
    (4) The board shall provide the approved monitoring program board orders requiring treatment, monitoring, and/or limitations on the practice of podiatric medicine and surgery for those participating in the program.
    [Statutory Authority: RCW 18.22.015 and chapter 18.22 RCW. WSR 94-14-082, § 246-922-410, filed 7/5/94, effective 8/5/94.]
RCW 18.22.015 and chapter 18.22 RCW. WSR 94-14-082, § 246-922-410, filed 7/5/94, effective 8/5/94.